3rd Annual Workshop on Genomics

The IMS Workshop on Genomics was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. Building upon this success, the Third IMS Genomics Meeting will be a public meeting led by global myeloma KOL.

The 2025 workshop will cover evolving evidence and clinical advances in myeloma, with a focus on drafting next-generation clinical studies and translational research based on data spanning multiple omics platforms and scales of resolution. The first day of the meeting will examine the state of science in myeloma precursor conditions, including SMM risk stratification and genomics of SMM/MGUS.  The second day will highlight how high-throughput technological advances can inform future translational and clinical research throughout the MM disease continuum.

Preliminary Program